Fabry Disease Treatment Market Overview:
Fabry disease treatment market was valued at USD 2.10 Billion in 2021, registering a CAGR of 10.2% during the forecast period (2022-2030), and is projected to be worth USD 5.03 Billion by 2030.
Fabry disease Market is a rare inherited disorder caused by a deficiency of the enzyme alpha-galactosidase A (alpha-GAL), which leads to the accumulation of a complex sugar called globotriaosylceramide (GL-3) in cells throughout the body. This accumulation leads to damage in various organs such as the heart, kidneys, nervous system, and skin. It is mostly seen in males, although females can also be affected.
The Fabry disease treatment market includes various therapies and treatments used to manage the symptoms and slow the progression of the disease, including enzyme replacement therapy (ERT) and pharmacological chaperone therapy.
The primary driver of the Fabry Disease Treatment Market is the increasing prevalence of the disease worldwide. According to the National Organization for Rare Disorders, Fabry disease occurs in approximately 1 in 40,000 to 60,000 males, and the incidence is lower in females. Additionally, the rising awareness among healthcare professionals and patients about the disease is driving the demand for early diagnosis and treatment.
Get Sample Report Here: https://marketresearchcommunity.com/sample-request/?rid=844
Pharmacological chaperone therapy is another treatment option for Fabry disease. It works by binding to and stabilizing the mutant enzyme, allowing it to function more effectively. The main pharmacological chaperone therapy is currently avaialble on the market is Galafold (migalastat).
There are several key players in the medication management market, including Avrobio Inc., Protalix Biotherapeutics Inc., Moderna Therapeutics Inc., and Greenovation Biotech GmbH, Shire Plc., Sanofi S.A., Amicus Therapeutics Inc., JCR Pharmaceuticals Co Ltd., ISU Abxis Co Ltd., Idorsia Pharmaceuticals Ltd.
The Fabry disease market study is categorized into major segments and further into sub-segments, such as
By Treatment
- Enzyme Replacement Therapy (ERT),
- Chaperone Treatment,
- Substrate Reduction Therapy (SRT),
- Others
By geography
- North America– (U.S., Canada, Mexico)
- Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)
- Latin America- (Brazil, Argentina, Chile, Rest of Latin America)
- The Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)
- Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)
The Fabry Disease Treatment Market presents several opportunities, including the development of new and innovative therapies, increasing awareness among healthcare professionals and patients, and expanding the market in developing countries. Additionally, the market presents opportunities for collaboration between pharmaceutical companies, research institutions, and patient organizations.
The Fabry disease treatment market Size is a small but growing market. It is expected to grow at a significant CAGR (compound annual growth rate) in the coming years, mainly due to the increasing incidence of Fabry disease, growing awareness about the disease, and the availability of new treatments.
Contact:
Market Research Community
